Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score

L. Smolej, P. Turcsányi, Z. Kubová, J. Zuchnická, J. Mihályová, M. Šimkovič, P. Vodárek, M. Krčméryová, H. Móciková, M. Brejcha, M. Špaček, Czech CLL Study Group

. 2021 ; 193 (1) : 133-137. [pub] 20200910

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21025876

Grant support
PROGRES Q40/08 Univerzita Karlova v Praze
FNHK, RVO 0017906 Ministerstvo zdravotnictví České republiky
VFN, RVO 64165 Ministerstvo zdravotnictví České republiky
Ministry of Health

Most patients with chronic lymphocytic leukaemia (CLL) are nowadays diagnosed without any symptoms and do not require therapy. A prognostic score identifying patients within this large group who are at high risk of disease progression would be highly beneficial. The recently published International Prognostic Score for Early asymptomatic patients (IPS-E) uses combination of absolute lymphocyte count (ALC) >15 × 109 /l, palpable lymphadenopathy, and unmutated immunoglobulin heavy-chain variable-region (IGHV) gene to predict the time to first-line therapy (TTFT). Patients at low, intermediate, and high risk had estimated 5-year TTFT of 8%, 28%, and 61%. We performed an external validation of the IPS-E score using an unselected, consecutive group of 130 Binet A patients. The 5-year TTFT was 11%, 36%, and 78% (C-statistic 0·74). Furthermore, we propose an alternative system (AIPS-E) using cytogenetic aberrations instead of palpable lymphadenopathy. This system yielded 5-year TTFT of 14%, 40%, and 72%. These results were externally validated in 388 Binet A patients from five Czech centres; the 5-year TTFT was 16%, 37%, and 80% (C-statistic 0·74). In conclusion, we have successfully validated the IPS-E score for patients with early stage CLL. In addition, we propose a modified scoring system, the AIPS-E, combining IGHV, fluorescence in situ hybridisation, and ALC.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025876
003      
CZ-PrNML
005      
20250114091351.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bjh.17074 $2 doi
035    __
$a (PubMed)33280081
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Smolej, Lukáš $u 4th Department of Internal Medicine - Haematology, University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic
245    10
$a External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score / $c L. Smolej, P. Turcsányi, Z. Kubová, J. Zuchnická, J. Mihályová, M. Šimkovič, P. Vodárek, M. Krčméryová, H. Móciková, M. Brejcha, M. Špaček, Czech CLL Study Group
520    9_
$a Most patients with chronic lymphocytic leukaemia (CLL) are nowadays diagnosed without any symptoms and do not require therapy. A prognostic score identifying patients within this large group who are at high risk of disease progression would be highly beneficial. The recently published International Prognostic Score for Early asymptomatic patients (IPS-E) uses combination of absolute lymphocyte count (ALC) >15 × 109 /l, palpable lymphadenopathy, and unmutated immunoglobulin heavy-chain variable-region (IGHV) gene to predict the time to first-line therapy (TTFT). Patients at low, intermediate, and high risk had estimated 5-year TTFT of 8%, 28%, and 61%. We performed an external validation of the IPS-E score using an unselected, consecutive group of 130 Binet A patients. The 5-year TTFT was 11%, 36%, and 78% (C-statistic 0·74). Furthermore, we propose an alternative system (AIPS-E) using cytogenetic aberrations instead of palpable lymphadenopathy. This system yielded 5-year TTFT of 14%, 40%, and 72%. These results were externally validated in 388 Binet A patients from five Czech centres; the 5-year TTFT was 16%, 37%, and 80% (C-statistic 0·74). In conclusion, we have successfully validated the IPS-E score for patients with early stage CLL. In addition, we propose a modified scoring system, the AIPS-E, combining IGHV, fluorescence in situ hybridisation, and ALC.
650    _2
$a senioři $7 D000368
650    _2
$a chromozomální aberace $x statistika a číselné údaje $7 D002869
650    _2
$a kohortové studie $7 D015331
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a geny pro těžké řetězce imunoglobulinů $x genetika $7 D050438
650    _2
$a lidé $7 D006801
650    _2
$a hybridizace in situ fluorescenční $x metody $7 D017404
650    _2
$a chronická lymfatická leukemie $x krev $x diagnóza $x mortalita $x patologie $7 D015451
650    _2
$a lymfadenopatie $x diagnóza $7 D000072281
650    _2
$a počet lymfocytů $x metody $7 D018655
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a staging nádorů $x metody $7 D009367
650    _2
$a palpace $x metody $7 D010173
650    _2
$a prognóza $7 D011379
650    _2
$a výzkumný projekt $x trendy $7 D012107
650    _2
$a rizikové faktory $7 D012307
650    _2
$a čas zasáhnout při rozvinutí nemoci $x statistika a číselné údaje $7 D061665
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Turcsányi, Peter $u Department of Haematology-Oncology, University Hospital, Olomouc, Czech Republic
700    1_
$a Kubová, Zuzana $u Department of Haematology-Oncology, University Hospital, Olomouc, Czech Republic
700    1_
$a Zuchnická, Jana $u Department of Haematooncology, University Hospital Ostrava and Faculty of Medicine, Ostrava University, Ostrava, Czech Republic
700    1_
$a Mihályová, Jana $u Department of Haematooncology, University Hospital Ostrava and Faculty of Medicine, Ostrava University, Ostrava, Czech Republic
700    1_
$a Šimkovič, Martin $u 4th Department of Internal Medicine - Haematology, University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic
700    1_
$a Vodárek, Pavel $u 4th Department of Internal Medicine - Haematology, University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic
700    1_
$a Krčméryová, Mária $u Department of Internal Medicine - Haematology, University Hospital Královské Vinohrady, Prague, Czech Republic
700    1_
$a Móciková, Heidi $u Department of Internal Medicine - Haematology, University Hospital Královské Vinohrady, Prague, Czech Republic
700    1_
$a Brejcha, Martin $u Department of Haematology, Oncology Center, Nový Jičín, Czech Republic, Prague, Czech Republic $7 xx0105595
700    1_
$a Špaček, Martin $u First Department of Medicine - Haematology, University General Hospital, Prague, Czech Republic
710    2_
$a Czech CLL Study Group
773    0_
$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 193, č. 1 (2021), s. 133-137
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33280081 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20250114091348 $b ABA008
999    __
$a ok $b bmc $g 1714779 $s 1146383
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 193 $c 1 $d 133-137 $e 20200910 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
GRA    __
$a PROGRES Q40/08 $p Univerzita Karlova v Praze
GRA    __
$a FNHK, RVO 0017906 $p Ministerstvo zdravotnictví České republiky
GRA    __
$a VFN, RVO 64165 $p Ministerstvo zdravotnictví České republiky
GRA    __
$p Ministry of Health
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Archiving options